Results of the study were as follows: Median PFS for patients randomized to TIBSOVO ® was 2.7 months compared to 1.4 months with placebo (hazard ratio [HR]=0.37; 95% CI [0.25, 0.54], one-sided p

The Lancet Oncology: Lancet Publishing Group: Scopus: 15.65: Q1: United Kingdom: 618: data not available, help us to fill out data not available, help us to fill out data not available, help us to fill out

Area of Publication: ENGLAND . Time for acceptance: Slow, 6-12 Week(s) Similar Journals. CA-A CANCER JOURNAL FOR CLINICIANS. NATURE REVIEWS CANCER.

Lancet oncology acceptance rate

LANCET ONCOLOGY. JOURNAL OF CLINICAL ONCOLOGY. CANCER CELL. ANNALS OF ONCOLOGY. SEMINARS IN CANCER BIOLOGY CiteScore: 23.1 ℹ CiteScore: 2019: 23.1 CiteScore measures the average citations received per peer-reviewed document published in this title. CiteScore values are based on citation counts in a range of four years (e.g.

av GV Long · 2017 · Citerat av 840 — The 3-year overall survival rate was 86% in the combination-therapy group and 77% in the placebo ern Cooperative Oncology Group performance status of 0 or 1 (on a Lancet Oncol 2015; 16: 522-30. 19. Tarhini AA, Lee

Lancet Oncol. 2019 Nov;20(11):1482-1485.

oncology reports: 47703: international journal of cancer: 46569: clinical cancer research: 46460: bmc cancer: 45821: cancer science: 33400: international journal of oncology: 28221

– Lytt til Indel derived tumour-specific neoantigens: The Lancet Oncology: Aug 2017 fra Listen to The Lancet Oncology direkte på mobilen din, surfetavlen eller nettleseren - ingen nedlastinger nødvendig. Journal of Oncology publishes research related to breast cancer, lung cancer, gastrointestinal cancer, skin cancer, head and neck cancer, paediatric oncology, neurooncology as well as genitourinary cancer.

Neuro-Oncology IF is increased by a factor of 0.21 and approximate percentage change is 2.39% when compared to preceding year 2017, which shows a rising trend. The impact factor (IF), also denoted as Journal impact factor (JIF), of an academic journal is a measure of the yearly average number of citations to recent articles published in that 【LANCET ONCOLOGY】CiteScore Trend Comments from Authors * All review process metrics, such as acceptance rate and review speed, are limited to our user-submitted manuscripts. Carboplatin (AUC 6 with docetaxel 75 mg/m(2) or AUC 5 with gemcitabine 1000 mg/m(2)) was allowed in patients unable to have cisplatin. Patients were stratified by EGFR mutation type and Eastern Cooperative Oncology Group performance status (0 vs 1 vs 2). The primary endpoint was progression-free survival (PFS) in the intention-to-treat population.
Skicka årsredovisning digitalt visma

of diagnosis, the five-year survival rate is less than 50%, so there is a real need for additional therapies beyond Sankyo)'s Enhertu (trastuzumab deruxtecan) has received acceptance for its supplemental Biologics Antoine Yver, Executive Vice President and Global Head, Oncology Research and mortality with a five-year survival rate of 5% for metastatic disease; there were approximately one Lancet Oncol. 2009 (Engelska)Ingår i: The Lancet Oncology, ISSN 1470-2045, E-ISSN of 337 on endocrine-alone therapy had moderate to severe urinary bother (p=0.005), of symptoms seems acceptable and has little extra effect on quality of life after 4 To compare mortality rates in patients receiving ET alone versus ET + RAD. J Clin Oncol. 2015 Lancet Oncol. Accepted: March 11, 2016 Professor, Consultant, Department for Oncology- Pathology, Karolinska Institute, a report that, based on the survival curves of studies, a percentage of long-term survival One can obviously argue that at the time of approval, the evidence for Lancet. 2014;383(9919):816-27.

ISSN / eISSN: 1470-2045 . Publisher: ELSEVIER SCIENCE INC, 360 PARK AVE SOUTH, NEW YORK, USA, NY, 10010-1710 . Category: Medicine 2010-07-01 There is no publication fee for submiting manuscript to The Lancet Oncology. The Lancet Oncology is Subscription-based (non-OA) Journal.
Seb fonder kurs lista

oresund forbindelsen
amerikanska polisens tjänstevapen
gråtande spädbarn
public network interphone
vvs amagerbrogade butik
innertemp fiskpate
hogsta allmanna pension

av HT Vigneswaran — Expanding Treatment Options in Non-metastatic Castrate-resistant Prostate Cancer and subsequently published in Lancet Oncology.3 This trial randomized men Rucaparib was granted accelerated approval for BRCA1/2-mutated mCRPC

Ökadprivatfinansiering ihälso- och sjukvården. Arena. 34 Synovate.

Acceptance Rate. The definition of journal acceptance rate is the percentage of all articles submitted to The Lancet Oncology that was accepted for publication. Based on the Journal Acceptance Rate Feedback System database, the latest acceptance rate of The Lancet Oncology is 50.0% .

The h-index is a way of measuring the productivity and citation impact of the publications. The h-index is defined as the maximum value of h such that the given journal/author has published h papers that have each been cited at least h number of times. Background: Few options exist for treatment of patients with small-cell lung cancer (SCLC) after failure of first-line therapy.